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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness and safety of BAS in the primary prevention of IHD in people with HeFH.
B A C K G R O U N D
Description of the condition
Familial hypercholesterolaemia (FH) is an inheritedmetabolic dis-
ease characterised by an elevated level of low density lipoprotein
(LDL) cholesterol. Historically, it has been shown that if left un-
treated, it will lead to at least 50% of men under 50 years old and
30% of women under 60 years old developing ischaemic heart
disease (IHD) (Slack 1969; Stone 1974). A more recent obser-
vational study showed that the presence of a causative FH mu-
tation may increase the risk of IHD six-fold as compared with
those with a similar cholesterol level with no mutation, and a 22-
fold risk comparedwith those with normocholesterolaemia (Khera
2016). FH is an autosomal dominant disorder with the severe ho-
mozygous form occurring in one in a million people and the less
severe heterozygote form (HeFH) in one in 200 to 500 people
(Nordestgaard 2013). Based on these prevalences, it is estimated
that FH affects between 13 and 34 million people worldwide;
however, due to differences in screening, in many countries less
than 1% of individuals have been diagnosed. The diagnosis of FH
is based on either clinical criteria or genetic testing (Ryan 2015).
Current registry data have shown early diagnosis and treatment
reduce the risk of early-onset IHD (Mundal 2014; Versmissen
2008). Current methods of risk assessment and treatment used
in clinical guidance are mainly adopted from non-FH guidelines
(Nordestgaard 2013).
Description of the intervention
Prior to the introduction of statin therapy, bile acid sequestrants
(BAS) were the first-line treatment in managing FH. Current
guidance recommends their use as a second- or third-line option
in those with statin intolerance or in those individuals failing to
achieve LDL targets on statins (Nordestgaard 2013). BAS are non-
absorbable resins that bind negatively charged bile acids in the
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intestinal lumen. This diverts bile acids from enterohepatic cy-
cling into the faeces for excretion (Insull 2006). The earlier BAS,
colestryramine and colestipol, were bulky and unpalatable with
doses in adults starting at 4 g to 5 g per day, gradually building up
to a maximum of 30 g to 36 g per day (taken in divided doses).
The newer BAS, colevelam, is less bulky with doses in adults up
to 3.75 g per day in divided doses and was designed to be more
palatable and potent than its predecessors (Davidson 1999).
As these drugs are not systemically absorbed, side effects aremainly
intestinal, causing constipation at higher doses and malabsorption
of fat-soluble vitamins and drugs such as thiazides, digoxin and
warfarin. It is possible to avoid such an interaction by altering the
timing of drug administration, e.g. taking them at least one hour
before or four to six hours after resin ingestion. Interestingly, BAS
may also increase triglycerides, particularly in those with already
elevated levels of very low density lipoprotein (VLDL), and hence
should be avoided in this group (Miller 1973).
How the intervention might work
Interruption in the enterohepatic recycling of bile acid synthesis
affects cholesterol metabolism in several ways (Einarsson 1991).
Increased faecal bile acid output is compensated by their increased
hepatic synthesis from cholesterol, which is a bile acid precur-
sor (Moutafis 1977). This effect is mainly driven by an increase
in cholesterol 7α hydroxylase, which is the rate-limiting step for
bile acid synthesis. This leads to an increase in the demand for
cholesterol by hepatocytes, thus increasing LDL receptor expres-
sion (Shepherd 1980). The plasma concentration of LDL is there-
fore lowered through a combination of these mechanisms; how-
ever, it is likely that the increase in LDL receptor expression is the
predominant mechanism as BAS lose efficacy in those individuals
with null LDL receptor expression (Betteridge 1992).
These resins, however, are believed to havemore than just an effect
on binding bile acids in the gut. They are thought to inactivate the
farnesoid X receptor to increase high density lipoprotein (HDL)
production and increase TG5 and GLP-1, thus decreasing fasting
glucose and Hba1c (Marina 2012; Potthoff 2013). These effects
may be of relevance where other lipid-lowering therapies have been
shown to increase risk of diabetes mellitus and are discussed below.
Why it is important to do this review
Recent guidance has highlighted the significant unmet need for
both diagnosing and treating FH. Observational data have iden-
tified that less than 50% of people with FH are on first-line statin
therapy, with similar numbers of individuals failing to achieve
LDL targets (Nordestgaard 2013). There is now a growing body
of evidence that suggests that additional therapy or alternatives to
statin therapy in FH are required (Nordestgaard 2013; Vallejo-Vaz
2016). A systematic review of BAS trials will help evaluate the role
of these drugs in the FH-patient care pathway.
There have been concerns regarding the potential diabetogenic ef-
fects of statins and more recently PCSK9 inhibitors as suggested
by a mendelian randomisation study, particularly in those with
pre-existing impaired fasting glucose (Lotta 2016). During trials
on dyslipidaemia in people with diabetes it was noted that BAS
improved glucose control by unknown mechanisms and there are
a number of trials exploring these positive effects on glycaemia
(Rosenstock 2012; Yamakawa 2007). There is also a growing body
of evidence to suggest that the risk of IHD in HeFH is also influ-
enced by traditional risk factors, such as hypertension, smoking
cigarettes and diabetes (Besseling 2014). This suggests that when
combined with standard therapy such as statins, any positive effect
on glucose may be of benefit and important to the FH-patient
care pathway.
A previous systematic review found that BAS reduced LDL with a
range of 9.6% to 20.6%; however, this included many studies of
less than 12 weeks duration and only one of these was in people
with FH, the rest being in people with diabetes (Mazidi 2017).
Davidson undertook a systematic review on BAS and FH in 2011;
however, this was limited to children and the evidence for adults
with FH remained unexplored (Davidson 2011). A mendelian
randomisation study on BAS in hypercholesterolaemia has sug-
gested an odds ratio of 0.63 for coronary artery disease; however,
FH received limited discussion (Ross 2015). This evidence sug-
gests that BAS have a beneficial effect on reducing risk of cardio-
vascular disease (CVD) in hypercholesterolaemia, but there is an
unmet need for a systematic review that explores the role of BAS
in the FH-patient pathway.
O B J E C T I V E S
To assess the effectiveness and safety of BAS in the primary pre-
vention of IHD in people with HeFH.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled clinical trials.
Types of participants
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People of all ages with FH diagnosed either genetically or clinically
(based on a referenced, validated FH clinical diagnosis scoring
system).
Types of interventions
Active treatment with a BAS (e.g. colsevalam, colestipol) com-
pared to either another BAS, placebo, diet, or with another lipid-
lowering agent (e.g. a statin, ezetimibe, or a PCSK9 inhibitor).
Eligible studies will be at least one year in duration, with a min-
imum follow-up of six months (Taylor 2013). This duration was
selected in order to provide safety data and longer-term outcome
data that would enhance current care for people with FH.
Types of outcome measures
Primary outcomes
1. CVD (a composite end-point defined as urgent coronary
revascularization, unstable angina pectoris, non-fatal and fatal
myocardial infarction and coronary heart disease death)*
2. Change from baseline in lipid parameters (total cholesterol,
LDL-C, HDL-C, triglycerides (mmol/L), apolipoprotein A1 (g/
L), apolipoprotein B (g/L) and lipoprotein[a] (mg/dL))
measured as both absolute (mmol/L) and relative (%) changes
where possible
* It is anticipated that such outcomes will not be available for those
under 18 years of age.
Secondary outcomes
1. Adverse events (including type 2 diabetes and cancer)
2. All-cause mortality
3. Myopathy or myalgia or creatinine kinase (CK) rise (units/
L)*
4. Fasting glucose (mmol/L) and HbA1c (mmol/mol)
5. Upper and lower gastrointestinal disturbance
* Myopathy is defined as any muscle symptom; myalgia where
muscle symptoms occur with CK within reference range; myositis
where muscle symptoms occur with CK above the reference range
(Pasternak 2002).
Search methods for identification of studies
We will search for all relevant published and unpublished studies
without restrictions on language, year or publication status.
Electronic searches
We will identify relevant studies from the Group’s Inborn Errors
of Metabolism Trials Register.
The Inborn Errors of Metabolism Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of the Cochrane
Library), weekly searches ofMEDLINE and the prospective hand-
searching of one journal - Journal of Inherited Metabolic Disease.
Unpublished work is identified by searching through the abstract
books of the Society for the Study of Inborn Errors of Metabolism
conference and the SHS Inborn Error Review Series. For full de-
tails of all searching activities for the register, please see the relevant
section of the Cochrane Cystic Fibrosis and Genetic Disorders
Group’s website.
We will search the following databases, registries and resources:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library
www.thecochranelibrary.com;
• Medline Ovid (1946 to present);
• Web of Science (1898 to present);
• US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch).
For the full search strategies, please see Appendix 1.
Searching other resources
We will check the bibliographies of included studies and any rele-
vant systematic reviews identified for further references to relevant
studies.
Data collection and analysis
Selection of studies
Two authors (AR and SN) will independently review the titles and
abstracts of articles found in the electronic searches for potentially
eligible studies for review. The same two authors will indepen-
dently assess the full manuscripts (if available) against the inclu-
sion criteria and, where necessary, resolve any disagreements with
discussion or the involvement of the third author (PC).
Data extraction and management
Two authors (AR and SN) will independently extract relevant pri-
mary and secondary outcomedata, with any disagreement resolved
either by discussion or by the involvement of the third author
(PC).
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Assessment of risk of bias in included studies
Two authors (AR and SN) will independently assess the risk of
bias, with any disagreement resolved either by discussion or by the
involvement of the third author (PC).Wewill assess the risk of bias
of individual RCTs using the Cochrane ’Risk of bias’ assessment
tool based on the following items.
• Random sequence generation
• Allocation concealment
• Intervention blinding
• Outcome blinding
• Missing outcome data
• Selective reporting
• Other biases
We will grade the individual items at ’low’, ’unclear’, or ’high’ risk
of bias (Higgins 2011a).
Measures of treatment effect
For binary outcome measures (such as adverse events), we will
calculate a pooled estimate of the treatment effect for each outcome
across studies using risk ratio (RR) and 95% confidence intervals
(CIs) where appropriate. If multiple adverse events are reported in
the included studies, we will use 99% CIs to account for multiple
statistical testing.
For continuous outcomes (such as lipid parameters and cognitive
function), we will record either the mean relative change from
baseline for each group or the mean post-treatment or post-in-
tervention values and the standard deviation (SD). If the papers
report standard errors (SE), we will convert these to SDs using the
methodology as described in chapter 7 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011b). We will
present a pooled estimate of treatment effect by calculating the
mean difference (MD) and 95% CIs. If we become aware that
some data are skewed and are not able to enter and analyse these
within the Review Manager (RevMan) software, we will report
these narratively (Deeks 2011). Where data are presented accord-
ing to different scales (e.g. cognitive functions), we will present
the standardised mean difference (SMD) and 95% CIs.
For any time-to-event outcomes included in the review (such as
all-cause mortality), we plan to extract the log hazard ratio (HR)
and SE estimates from the studies and we aim to combine all the
results using the generic inverse variance method. If log HRs are
not available, we will extract the log rank P value estimates or
survival curve estimates to convert into logHRs and SEs as detailed
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011c).
Unit of analysis issues
Cross-over studies and clustered randomised studies are not ap-
propriate designs and we will not be evaluating these in this review.
If eligible studies have more than one intervention or control arm
(e.g. two different BAS compared to a control treatment), we will
make separate comparisons of each BAS invention compared to
each control to avoid duplication of participants in the analysis.
Dealing with missing data
Where possible, we will report the numbers and reasons for drop-
outs and withdrawals in all intervention groups. We will contact
authors for clarification on missing information where possible.
In order to allow an intention-to-treat analysis, we will seek data
on the number of participants within each outcome event, by
allocated treatment group, irrespective of compliance and whether
or not the individual is later thought to be ineligible or otherwise
excluded from treatment or follow-up (Higgins 2011d).
Assessment of heterogeneity
We will assess between-study clinical heterogeneity by examining
differences in study designs, participant characteristics, direction
of treatment effect and overlap of CIs on forest plots
We will assess the between-study statistical heterogeneity using
the I² statistic and Tau², the latter calculated from random effects
meta-analysis.
We will interpret an I² statistic greater than 50% as an indica-
tion of important heterogeneity. Where important heterogene-
ity is present between studies, we will perform random-effects
meta-analysis and we will explore potential sources of hetero-
geneity through subgroup analysis (see Subgroup analysis and
investigation of heterogeneity).
Where very high levels of between-study heterogeneity are present
(I² statistic greater than 75%) which cannot be readily explained,
we will not perform meta-analyses. Instead, we will perform a
narrative review (Higgins 2003).
Assessment of reporting biases
If we are able to include a sufficient number of studies (10 or
more as recommended by the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011e)), we will attempt to assess
whether our review is subject to publication bias by using a funnel
plot. If asymmetry is detected, we will explore causes other than
publication bias.
Data synthesis
If we identify important levels of heterogeneity (as defined above),
we will present pooled estimates of the treatment effect using a
random-effects model. If this level of heterogeneity is not identi-
fied, we will compute pooled estimates of the treatment effect for
each outcome under a fixed-effect model (Deeks 2011).
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Subgroup analysis and investigation of heterogeneity
We will determine the consistency of the effects of BAS on major
cardiovascular events for the following subgroups:
• gender;
• age (under 18 years of age or 18 years and over);
• baseline characteristics (presence of diabetes; LDL-C level
(continuous and above 2.5 mmol/L); body mass index (BMI)
(less than 25, 25 to 29.99, 30 or more);
• FH genotype.
If we are able to include a sufficient number of studies and such
an analysis is deemed appropriate, we will employ meta-regression
(weighted for the inverse variance weights (Thompson 2002)) to
explore whether treatment effects differ between study baseline
characteristics on a continuous scale.
Sensitivity analysis
In order to assess the validity and robustness of the review’s results,
we will perform sensitivity analyses excluding studies at high risk
of bias for one or more domains and compare the direction and
magnitude of results of the sensitivity analyses to that of the pri-
mary analyses (Deeks 2011).
Summary of findings and quality of the evidence
(GRADE)
We will present a summary of findings table for each compari-
son made in the review. The following outcomes will be reported
in all tables (chosen based on relevance to clinicians and con-
sumers): CVD (composite endpoint); lipid parameters; adverse
events; all-cause mortality; changes in fasting glucose (mmol/L)
and HbA1C(mmol/mol). We will also note the genotype of the
underlying mutation for HeFH.
We will determine the quality of the evidence using the GRADE
approach; anddowngrade evidence in the presence of: a high risk of
bias in at least one study; indirectness of the evidence; unexplained
heterogeneity or inconsistency; imprecision of results; or a high
probability of publication bias. We will downgrade the evidence
by one level if we consider the limitation to be serious and by two
levels if very serious.
We will present results in the summary of findings tables in the
most appropriate way for the data available (e.g. if included studies
report multiple adverse events, we will make a general statement
regarding all reported adverse events rather than considering each
event separately for brevity and clarity in the tables) (Shemilt
2011).
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A P P E N D I C E S
Appendix 1. Search methods - electronic searches
Database/ Resource Strategy
CENTRAL (via the Cochrane Library) [Search Manager Form]
#1 MeSH descriptor: [Hyperlipoproteinemia Type II] this term only
#2 (familial or inherited) near/2 (hypercholesterol*mia*)
#3 (Hyperlipoprotein*mia*) near/2 (type II or type IIa or type IIb or type 2 or type 2a or
type 2b)
#4 #1 or #2 or #3
#5 sequestrant*
#6 BAS
#7 (Colesevelam or Cholestagel or Welchol or Lodalis)
#8 MeSH descriptor: [Colesevelam Hydrochloride] this term only
#9 (Colestipol or Colestid or Cholestabyl)
7Bile acid sequestrants for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#10 MeSH descriptor: [Colestipol] this term only
#11 (Cholestyramine or Colestyramine or Questran or Prevalite)
#12 MeSH descriptor: [Cholestyramine Resin] this term only
#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 #4 and #13
Medline Ovid (1946 to present) 1. ((familial or inherited) adj2 hypercholesterol?emia$).tw.
2. Hyperlipoproteinemia Type II/
3. (Hyperlipoprotein?emia$ adj (type II or type IIa or type IIb or type 2 or type 2a or type
2b)).tw
4. 1 or 2 or 3
5. sequestrant$.tw.
6. BAS.tw.
7. (Colesevelam or Cholestagel or Welchol or Lodalis).tw.
8. Colesevelam Hydrochloride/
9. (Colestipol or Colestid or Cholestabyl).tw.
10. Colestipol/
11. (Cholestyramine or Colestyramine or Questran or Prevalite).tw
12. Cholestyramine Resin/
13. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. randomized controlled trial.pt.
15. controlled clinical trial.pt.
16. randomized.ab.
17. placebo.ab.
18. drug therapy.fs.
19. randomly.ab.
20. trial.ab.
21. groups.ab.
22. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. exp animals/ not humans.sh.
24. 22 not 23
25. 4 and 13 and 24
NOTE: Lines #16- #24 are the Cochrane Highly Sensitive Search Strategy for identifying
randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); Ovid
format
Web of Science (1898 to present) #1 TS=((familial or inherited) NEAR/2 hypercholesterol*emia*)
#2 TS=Hyperlipoprotein*emia*
#3 TS=(type II OR type IIa OR type IIb OR type 2 OR type 2a OR type 2b)
#4 #3 AND #2
#5 #4 OR #1
#6 TS=(sequestrant* OR BAS OR Colesevelam OR Cholestagel ORWelchol OR Lodalis
OR Colestipol OR Colestid OR Cholestabyl OR Cholestyramine OR Colestyramine OR
Questran OR Prevalite)
#7 #6 AND #5
#8TS= clinical trial*ORTS=research designORTS=comparative stud*ORTS=evaluation
stud* OR TS=controlled trial* OR TS=follow-up stud* OR TS=prospective stud* OR
TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*) OR TS=
(triple blind*) OR TS=(treble blind*) or TS=(singleblind*) OR TS=(doubleblind*) OR
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(Continued)
TS=(tripleblind*) OR TS=(trebleblind*) OR TS=blinded OR TS=cross* OR TS=RCT
#9 #8 AND #7
Note: Line #8 is based on a filter from University of Alberta Libraries http://guides.library.
ualberta.ca/c.php?g=248586&p=1655962 (accessed 05 Oct 2017)
ClinicalTrials.gov [Advanced Search form]
OTHERTERMS: sequestrant OR sequestrants ORBASORColesevelamORCholestagel
ORWelcholOR Lodalis ORColestipol ORColestid ORCholestabyl ORCholestyramine
OR Colestyramine OR Questran OR Prevalite
STUDY TYPE: Interventional Studies
CONDITION/ DISEASE: hypercholesterolemia OR hypercholesterolaemia OR Hyper-
lipoproteinemia OR Hyperlipoproteinaemia
WHO ICTRP [Advanced Search Form]
CONDITION: hypercholesterolemia OR hypercholesterolaemia OR Hyperlipoproteine-
mia OR Hyperlipoproteinaemia
INTERVENTION: sequestrant OR sequestrants OR Colesevelam OR Cholestagel OR
Welchol OR Lodalis OR Colestipol OR Colestid OR Cholestabyl OR Cholestyramine
OR Colestyramine OR Questran OR Prevalite
RECRUITMENT STATUS: All
C O N T R I B U T I O N S O F A U T H O R S
AR drafted the protocol with input from the other authors.
D E C L A R A T I O N S O F I N T E R E S T
All authors: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
10Bile acid sequestrants for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
